USPTO issues notice of allowance to Vermillion's breast cancer biomarkers

NewsGuard 100/100 Score
Feb 2 2011

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of breast cancer and to the measurement of the biomarkers by mass spectrometry.

"The notice of allowance for this breast cancer biomarker patent is additional validation of our approach to intellectual property protection. We view the increasing breadth of our patent portfolio as a significant corporate asset," said Gail S. Page, CEO and Chairperson of the Board of Directors of Vermillion.

Source:

Vermillion, Inc

Posted in: Medical Science News | Medical Condition News | Medical Patent News

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

DASH diet may lower the risk of cardiovascular disease in breast cancer survivors
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery
Breast cancer survivors at higher risk of developing second cancers
MONET: New AI tool enhances medical imaging with deep learning and text analysis
Breakthrough imaging method enhances precision in prostate cancer treatment
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact
Study links air pollution to increased colorectal cancer risk through DNA changes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels